TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-919-7658400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings results on Tuesday, February, 26th. The medical instruments supplier reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01. The medical instruments supplier earned $7.50 million during the quarter, compared to analyst estimates of $7.35 million. The business's revenue for the quarter was up 120.6% compared to the same quarter last year. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What guidance has TransEnterix issued on next quarter's earnings?
TransEnterix issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $24-24 million, compared to the consensus revenue estimate of $23.89 million.TransEnterix also updated its Q4 2018 guidance to EPS.
What price target have analysts set for TRXC?
3 equities research analysts have issued 1-year price objectives for TransEnterix's shares. Their forecasts range from $5.00 to $5.50. On average, they expect TransEnterix's share price to reach $5.25 in the next year. This suggests a possible upside of 136.5% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.
What are Wall Street analysts saying about TransEnterix stock?
Here are some recent quotes from research analysts about TransEnterix stock:
- 1. According to Zacks Investment Research, "TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. " (1/11/2019)
- 2. BTIG Research analysts commented, "with TransEnterix announced the acquisition of MST Israeli company that has created an image analytics technology that uses artificial intelligence, scene recognition, and machine learning. With the cash + stock transaction (worth ~$33M as of 9/21 closing price) expected to close in Q4, TRXC will pick up the IP portfolio (30 patents, 31 pending), technology assets, and MST’s employees. Though the co’s AutoLap platform has FDA 510(k) and CE Mark clearance, TRXC does not intend to sell it as a standalone product. Instead, its capabilities— including dynamic 3D digital measurement, auto zoom, and anatomical structure identification—will be integrated into Senhance. Timing for these enhancements is unclear, though it is likely to take quarters, not years. We see this as an exciting step toward advanced digital laparoscopy, but our near-term focus remains on system sales." (9/25/2018)
Has TransEnterix been receiving favorable news coverage?
Headlines about TRXC stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TransEnterix earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the next several days.
Are investors shorting TransEnterix?
TransEnterix saw a increase in short interest in February. As of February 28th, there was short interest totalling 39,056,734 shares, an increase of 3.8% from the February 15th total of 37,612,193 shares. Based on an average trading volume of 4,690,069 shares, the days-to-cover ratio is presently 8.3 days. Currently, 21.8% of the company's stock are short sold. View TransEnterix's Current Options Chain.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include RESMED/IDR UNRESTR (RMD), Nanosonics (NAN), Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), Bovie Medical (BVX), Bovie Medical (BVX), CRH Medical (CRHM), Tristel (TSTL), SDI (SDI), InfuSystem (INFU), Daxor (DXR), TSO3 (TOS), IsoRay (ISR) and IsoRay (ISR).
What other stocks do shareholders of TransEnterix own?
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.35%), Mirae Asset Global Investments Co. Ltd. (2.02%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.84%), Geode Capital Management LLC (0.84%) and Masters Capital Management LLC (0.81%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, Todd Pope, Willam N Kelley and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.
Which institutional investors are selling TransEnterix stock?
TRXC stock was sold by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Eagle Asset Management Inc., California Public Employees Retirement System, Barclays PLC, MetLife Investment Advisors LLC, Jane Street Group LLC, New York State Common Retirement Fund and Two Sigma Advisers LP. Company insiders that have sold TransEnterix company stock in the last year include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Insider Buying and Selling for TransEnterix.
Which institutional investors are buying TransEnterix stock?
TRXC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Masters Capital Management LLC, Bank of New York Mellon Corp, Geode Capital Management LLC, Geode Capital Management LLC, HRT Financial LLC and Rhumbline Advisers. Company insiders that have bought TransEnterix stock in the last two years include Richard C Pfenniger Jr and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $2.22.
How big of a company is TransEnterix?
TransEnterix has a market capitalization of $481.83 million.
What is TransEnterix's official website?
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
